KRAS and neoplasm: For instance, the DDR1 inhibitor 3-(2-(pyrazolo[1,5-a] pyrimidin-6-yl) ethynyl) benzamide (7rh) significantly reduced tumor growth in gastric cancer xenografts (Hur et al., 2017), tumor burden in KRAS-driven lung adenocarcinoma (Ambrogio et al., 2016) and reduced primary tumor burden and improved chemoresponse in pancreatic ductal adenocarcinoma (Aguilera et al., 2017).